Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 19/20 | 0.70 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.57 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | GRK6 | P43250 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29794656 | 1.00 | NTRK1 (0.70) | NTRK1NTRK3NTRK2CYP1A2CYP2D6 | |
| SCHEMBL23217099 | 1.00 | NTRK1 (0.70) | NTRK1NTRK3NTRK2CYP1A2CYP2D6 | |
| SCHEMBL4076751 | 0.93 | NTRK1 (0.66) | NTRK1NTRK3NTRK2CYP1A2CYP2D6 | |
| SCHEMBL4073828 | 0.89 | NTRK1 (0.63) | NTRK1NTRK3NTRK2CYP1A2CYP2D6 | |
| SCHEMBL4069819 | 0.89 | NTRK1 (0.63) | NTRK1NTRK3NTRK2CYP1A2CYP2D6 | |
| SCHEMBL4068937 | 0.87 | NTRK1 (0.72) | NTRK1NTRK3NTRK2CYP1A2CYP2D6 | |
| SCHEMBL4069073 | 0.86 | NTRK1 (0.72) | NTRK1 | |
| SCHEMBL4149345 | 0.86 | NTRK1 (0.66) | NTRK1 | |
| SCHEMBL4151812 | 0.86 | NTRK1 (0.70) | NTRK1NTRK3NTRK2 | |
| SCHEMBL4070713 | 0.85 | NTRK1 (0.63) | NTRK1GRK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152219-A1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTRAZENECA R&D (SE) | 2010-06-17 | — | — | US | claimed |
| EP-1686999-B1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTRAZENECA AB (SE) | 2009-07-01 | — | — | EP | claimed |
| US-20090005396-A1 | Use of Pyrazolyl-Pyrimidine Derivatives in the Treatment of Pain | ASTRAZENECA AB (SE) | 2009-01-01 | — | — | US | claimed |
| EP-1877057-A1 | USE OF PYRAZOLYL-PYRIMIDINE DERIVATIVES IN THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2008-01-16 | — | — | EP | claimed |
| US-20070142413-A1 | Pyrazole derivatives as inhibitors of receptor tyrosone kinases | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | US | claimed |
| JP-2007511589-A | — | — | 2007-05-10 | — | — | JP | claimed |
| WO-2006115452-A1 | USE OF PYRAZOLYL-PYRIMIDINE DERIVATIVES IN THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2006-11-02 | — | — | WO | claimed |
| EP-1686999-A1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | AstraZeneca AB (SE) | 2006-08-09 | — | — | EP | claimed |
| WO-2005049033-A1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSYNE KINASES | ASTRAZENECA AB (SE) | 2005-06-02 | — | — | WO | claimed |
| US-20240158756-A1 | FEEDER-BASED AND FEEDER-FREE STEM CELL CULTURE SYSTEMS FOR STRATIFIED EPITHELIAL STEM CELLS, AND USES RELATED THERETO | UNIVERSITY OF HOUSTON SYSTEM (US) | 2024-05-16 | — | — | US | disclosed |
| CN-114945378-A | Feeder-layer and feeder-layer-free stem cell culture systems for stratified epithelial stem cells and uses related thereto | 休斯敦大学体系 | 2022-08-26 | — | — | CN | disclosed |
| US-20210164055-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | ARRAY BIOPHARMA, INC. | 2021-06-03 | — | — | US | disclosed |
| WO-2021072238-A1 | FEEDER-BASED AND FEEDER-FREE STEM CELL CULTURE SYSTEMS FOR STRATIFIED EPITHELIAL STEM CELLS, AND USES RELATED THERETO | UNIVERSITY OF HOUSTON SYSTEM (US) | 2021-04-15 | — | — | WO | disclosed |
| US-10907215-B2 | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same | LOXO ONCOLOGY, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20090005396-A1 | Use of Pyrazolyl-Pyrimidine Derivatives in the Treatment of Pain | ASTRAZENECA AB (SE) | 2009-01-01 | — | — | US | disclosed |
| EP-1877057-A1 | USE OF PYRAZOLYL-PYRIMIDINE DERIVATIVES IN THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2008-01-16 | — | — | EP | disclosed |
| US-20070142413-A1 | Pyrazole derivatives as inhibitors of receptor tyrosone kinases | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | US | disclosed |
| WO-2006115452-A1 | USE OF PYRAZOLYL-PYRIMIDINE DERIVATIVES IN THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2006-11-02 | — | — | WO | disclosed |
| EP-1686999-A1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | AstraZeneca AB (SE) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005049033-A1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSYNE KINASES | ASTRAZENECA AB (SE) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152219-A1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | LTK, ERBB2, ERBB3 | NTRK1 7/4885NTRK3 12/4885NTRK2 97/4885 |
| US-10907215-B2 | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same | NTRK3, NTRK1, NTRK2 | NTRK1 2/4885NTRK3 1/4885NTRK2 3/4885 |
| US-20210164055-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | NTRK3, NTRK1, NTRK2 | NTRK1 2/4885NTRK3 1/4885NTRK2 3/4885 |
| US-20070142413-A1 | Pyrazole derivatives as inhibitors of receptor tyrosone kinases | PRKDC, MUSK, LTK | NTRK1 15/4885NTRK3 18/4885NTRK2 132/4885 |
| US-20090005396-A1 | Use of Pyrazolyl-Pyrimidine Derivatives in the Treatment of Pain | P2RX3, DPYD, TYMP | NTRK1 3656/4885NTRK3 3193/4885NTRK2 2479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.